Despite being the standard of care in ER+ breast cancer, the molecular underpinnings of the benefit achieved with the use of endocrine therapies and CDK4/6 inhibitors as well as the mediators of resistance to these agents remain largely unknown. This evidence concerns the gene CDK4 and breast cancer.